|
|
|
| Relationship between the Efficacy of Risperidone in the Treatment of Schizophrenia and Dopamine D2 Receptor Gene Polymorphism |
| YU Xiang-man, LI Zhi-hua |
| Ankang Central Hospital, Ankang Shaanxi, 725000 |
|
|
|
|
Abstract 【Objective】To investigate the relationship between the efficacy of risperidone in the treatment of schizophrenia and the polymorphism of dopamine D2 receptor gene (DRD2). 【Methods】A total of 68 schizophrenic patients treated in our hospital from October 2018 to October 2019 was selected as the research objects. They were treated with risperidone for 8 weeks. The efficacy of risperidone was evaluated by positive and negative symptom scale (PANSS). According to PANSS, they were divided into total effective group and ineffective group, negative symptom effective group and ineffective group, positive symptom effective group and ineffective group. The genotypes and allele frequencies of rs6275 and rs6277 in DRD2 receptor gene of 68 patients were detected by single nucleotide polymorphism (SNP). 【Results】The total score, positive symptom score, negative symptom score and general psychopathology of 68 patients after treatment were significantly lower than those before treatment (P<0.05). Risperidone was effective in 52 cases and ineffective in 16 cases; Positive symptoms were effective in 54 cases and ineffective in 14 cases; Negative symptoms were effective in 53 cases and ineffective in 15 cases. There was no significant difference in gender, age and course of disease among different treatment groups (P>0.05).There were significant differences in the total efficacy of different genotypes of rs6275 between the effective group and the ineffective group, as well as the distribution of CC, CT, TT and alleles C and T (P<0.05).There were significant differences in the total efficacy of different genotypes of rs6277 between the effective group and the ineffective group, and the distribution of CC, CT, TT and allele C and T positive symptoms between the effective group and the ineffective group (P<0.05).【Conclusion】DRD2 gene polymorphism is related to the clinical efficacy of risperidone in the treatment of schizophrenia. Individualized drug regimens can be given to schizophrenic patients according to different DRD2 gene polymorphisms.
|
|
Received: 03 November 2020
|
|
|
|
|
|
[1] 仲照希, 吕路线, 王丽莎. 多巴胺D2受体基因多态性与利培酮疗效、锥体外系副反应及治疗前后泌乳素水平变化的关联分析[J].中国神经精神疾病杂志, 2008, 34(1):51-52.
[2] 谢国军, 陈家强, 黎雪松,等. 难治性精神分裂症患者多巴胺D1受体基因多态性对氯氮平疗效的影响[J].中华行为医学与脑科学杂志, 2016, 21(3):241-243.
[3] 潘丽红.精神分裂症患者多巴胺D2受体基因多态性与利培酮治疗效应的关联分析[J].临床精神医学杂志, 2019,29(3):161-164.[4] 舒良. 精神分裂症防治指南[M]. 北京:北京大学医学出版社, 2007.
[5] 张开元, 宋明芬, 陶云海,等. 精神分裂症脑源性神经营养因子基因C270T多态性与利培酮临床疗效的关联性研究[J].中国临床药理学杂志, 2016, 32(1):23-25.
[6] 杨鸽, 李文强, 张红星, 等. 细胞色素P450 2D6及多巴胺D2受体基因多态性与利培酮疗效的关联[J].中国神经精神疾病杂志, 2012, 38(10):609-611.
[7] BYRNE K A, DAVIS T, WORTHY D A. Dopaminergic genetic polymorphisms predict rule-based category learning[J].J Cogn Neurosci,2016,28(7):959-970.
[8] HAN J,LI Y,WANG X. Potential link between genetic polymorphisms of catechol-O-methyltransferase and dopamine receptors and treatment efficacy of risperidone on schizophrenia[J].Schizophr Res,2016,173(1-2):94-100.
[9] 李瑞芳, 李宏, 郭春阳,等. mRNA环结构对蛋白质折叠速率的影响[J].生物化学与生物物理进展, 2018, 45(6):672-678.
[10] 苏邹,丁迎,陈婷婷,等.ZNF804A 基因多态性对汉族精神分裂症患者帕利哌酮血药浓度的影响[J].精神医学杂志,2018,31(1):45-47. |
|
|
|
2021, Vol. 38 
